Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HitGen Partners with Nitrase to Develop Novel Enzyme Inhibitors

publication date: Dec 12, 2022

Chengdu HitGen formed a partnership with Nitrase Therapeutics, a San Francisco area company, to discover candidates for a new class of enzymes, nitrases, identified by the company. Nitrase says nitrases seem implicated in Parkinson's, cancer, respiratory diseases, fibrosis and other neurodegenerative diseases. The company’s NITROME platform has generated leads to inhibit nitrase enzymatic reactions to stopping protein nitration. HitGen will apply its DNA-encoded library platform to discover compounds that bind targets of interest to Nitrase. HitGen will receive an upfront payment and will be eligible for milestone payments from Nitrase. More detail....

Stock  Symbol: (SHA: 688222)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital